<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268033</url>
  </required_header>
  <id_info>
    <org_study_id>I08013</org_study_id>
    <nct_id>NCT01268033</nct_id>
  </id_info>
  <brief_title>Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood</brief_title>
  <acronym>NEPHRUTIX</acronym>
  <official_title>A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background

      Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with
      immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).

      Renal function of patients suffering from severe, steroid-dependent nephrotic syndrome with
      failure or toxic side effects of other immunosuppressant treatments is a major matter of
      concern.

      Cyclosporine endangers renal parenchyma (fibrosis) in these patients who must take this
      treatment for years. At the same time, low doses of cyclosporine allow proteinuria to
      reappear, which provokes degradation of renal function by focal segmental glomerulosclerosis.
      Some recent data lead to the conclusion that Rituximab may be effective in such a disease,
      with a cyclosporin sparing effect.

      Purpose

      The aim of the study is to evaluate the efficacy of Rituximab versus placebo in the treatment
      of pediatric patients suffering from severe cyclosporine-dependent nephrotic syndrome.

      Abstract Patients will be included in the study in a period of remission of proteinuria. Two
      infusions of Rituximab - at the dose of 375 mg/m²- or placebo will be administered at one
      week of interval. Other immunosuppressant treatments will be gradually tapered off with the
      same tapering pattern in both groups. In case of relapse of nephrotic syndrome, the blinding
      code will be broken. Rituximab will then be infused to patients having received placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After infusions of Rituximab or placebo, patients will be examined by their nephrologist on a
      monthly basis during five months. Follow up will be focused on proteinuria, albuminemia,
      lymphocyte phenotyping and Rituximab pharmacokinetics
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria with relapse of nephrotic syndrome (Serum albumin &lt; 30 g/L) within 5 months</measure>
    <time_frame>5 months</time_frame>
    <description>Proteinuria with relapse of nephrotic syndrome (Serum albumin &lt; 30 g/L) within 5 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- dosing of rituximab for toxicity during and/or after infusion</measure>
    <time_frame>5 months</time_frame>
    <description>- toxicity during and/or after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- dosing of rituximab for pharmacokinetics</measure>
    <time_frame>5 months</time_frame>
    <description>- dosing of rituximab for pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- dosing of lymphocyte</measure>
    <time_frame>5 months</time_frame>
    <description>- lymphocyte phenotyping</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of life inventory</measure>
    <time_frame>5 months</time_frame>
    <description>Pediatric Quality of life inventory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Childhood Idiopathic Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two infusions of Rituximab - at the dose of 375 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two infusions of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>two infusions - at the dose of 375 mg/m²- will be administered at one week of interval</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patients over 2 and under 18 years, with an idiopathic nephrotic
             syndrome (NS)

          -  Steroid Sensitive Nephrotic Syndrome (according to the French pediatric protocol).

        NEPHRUTIX

          -  Calcineurin inhibitor Dependent NS or NS for which anticalcineurin treatment has not
             been effective. Others immunosuppressive treatments (MMF) must have failed to control
             the disease activity.

          -  Effective contraception for girls of childbearing age.

          -  The patient is able to understand and has signed a written informed consent OR the
             parent or legal guardian is able to understand and has signed a written informed
             consent, which must be obtained prior to the initiation of any study procedure

        Exclusion Criteria:

          -  Terminal renal failure requiring dialysis/transplantation

          -  Transcutaneous oxygen stauration &lt; 97%

          -  Clinical or Radiological brochopulmonar or pleural abnormality

          -  Asymptomatic carrier of Hepatitis B virus our history of Hepatitis B

          -  Contraindication to Rituximab (RTX)

          -  Parents/patient refusing to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent GUIGONIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Fabiola Universitary Children's Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU REIMS - American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rituximab</keyword>
  <keyword>idiopathic nephrotic syndrome</keyword>
  <keyword>minimal change disease</keyword>
  <keyword>focal and segmental glomerulosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

